All News
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Janet Pope Janetbirdope ( View Tweet)
Review of the Scleroderma spectrum disorders (full-read) https://t.co/Z7cUrVeGRR https://t.co/VkYag0uZnX https://t.co/QK6bfcYBoF
Dr. John Cush RheumNow ( View Tweet)
Review of the Scleroderma spectrum disorders (full-read) https://t.co/Z7cUrVeGRR https://t.co/VkYag0uZnX https://t.co/QK6bfcYBoF
Links:
Dr. John Cush RheumNow ( View Tweet)
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Read Article
Systemic sclerosis sine scleroderma in children is more aggressive than in adults. 18 juvenile vs 38 adults - ssJSSc more female (39% vs 89%), more digital pitting scars/ulcers (35 vs 10.5%), Pulm (50 vs 24) & CV (50 vs 3%); w/ more deaths https://t.co/l4f5bH1IX1 https://t.co/viQcD3tN9V
Dr. John Cush RheumNow ( View Tweet)
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort
https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort
https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4
Nelly ZIADE 🍀 Nellziade ( View Tweet)
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Read Article
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt
Links:
Dr. John Cush RheumNow ( View Tweet)
"Don't You Know Who I am?" (5.17.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
Read Article
Who is confused about what to do for #GI symptoms in #scleroderma? @TimKanieckiMD does a masterful breakdown of gut involvement for @jhrheumatology rounds. You can read further in: https://t.co/xw6EElGIWl
@ZsuzsannaM55365 would be proud!
#MentoredResearchProjects
#dysmotility https://t.co/yLVD7Vo1SJ
Johns Hopkins Rheumatology Fellows JHRheumFellows ( View Tweet)
Who is confused about what to do for #GI symptoms in #scleroderma? @TimKanieckiMD does a masterful breakdown of gut involvement for @jhrheumatology rounds. You can read further in: https://t.co/xw6EElGIWl
@ZsuzsannaM55365 would be proud!
#MentoredResearchProjects
#dysmotility https://t.co/yLVD7Vo1SJ
Johns Hopkins Rheumatology Fellows JHRheumFellows ( View Tweet)
IL-1 recept accessory protein (IL1RAP) shown to block mediators (IL-1, IL33, IL36) that may drive systemic sclerosis. In vitro, IL1RAP inhibited fibroblasts and endothelial cells; in mouse models of SSc anti-IL1RAP decr dermal & pulmonary fibrosis. https://t.co/6YE02P4rjR https://t.co/mzw7t88Jzl
Dr. John Cush RheumNow ( View Tweet)
Epigenetics and Autoimmune Skin Disease
The central dogma proposed that genetic information predominantly transfers from DNA to RNA during gene expression to make a functional product protein.
https://t.co/VgQE2yYYmq https://t.co/fAWBifCyWv
Dr. John Cush RheumNow ( View Tweet)
Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/Vo5jIHBrPj https://t.co/TXvFypbZdw
Dr. John Cush RheumNow ( View Tweet)
FDA grants orphan drug designation to CAR T-cell therapy for systemic sclerosis https://t.co/KZKSy2sbNk https://t.co/5abz8MeYGK
Dr. John Cush RheumNow ( View Tweet)
Review of autoimmune Dz & adverse preg outcomes: Incr risk of:
- Miscarriage w/ Sjögrens (RR 8.85) & SLE (OR 4.9)
- Preeclampsia w/ SLE (OR 3.2)
- IUGR w/ scleroderma (OR 3.2) & celiac (OR 1.71)
- Preterm birth w/ SLE (OR 2.79).
https://t.co/bll2x2aS9Z https://t.co/Eg0sVBcPmR
Dr. John Cush RheumNow ( View Tweet)
Immunosuppression Increasing (2.23.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.
Read Article
CD19 CAR T-Cell Therapy in Autoimmune Disease
The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.
Read Article
Study of 43 SSc patients w/ gangrene shows Smoking Hx ; positive-ACA, ANCA, APL Abs & high ESR were independent risk factors for digital gangrenes in SSc. Vasculitis and macrovascular disease may contribute to the progression of digital gangrene https://t.co/3DY2Hx19s0 https://t.co/BfXANmckwF
Dr. John Cush RheumNow ( View Tweet)